vs
Side-by-side financial comparison of Solowin Holdings, Ltd. (AXG) and BioXcel Therapeutics, Inc. (BTAI). Click either name above to swap in a different company.
Solowin Holdings, Ltd. is the larger business by last-quarter revenue ($410.0K vs $256.0K, roughly 1.6× BioXcel Therapeutics, Inc.).
BioXcel Therapeutics, Inc. is a clinical-stage biopharmaceutical firm that leverages artificial intelligence to accelerate drug discovery and development. Its core focus is on neuroscience and immuno-oncology therapies addressing unmet medical needs, primarily serving markets in North America with candidates targeting rare and hard-to-treat conditions.
AXG vs BTAI — Head-to-Head
Income Statement — Q2 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $410.0K | $256.0K |
| Net Profit | — | $-12.5M |
| Gross Margin | — | 87.5% |
| Operating Margin | -34.1% | -4016.4% |
| Net Margin | — | -4900.4% |
| Revenue YoY | — | -30.1% |
| Net Profit YoY | — | -15.5% |
| EPS (diluted) | — | $0.40 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $256.0K | ||
| Q3 25 | — | $98.0K | ||
| Q2 25 | — | $120.0K | ||
| Q1 25 | — | $168.0K | ||
| Q4 24 | — | $366.0K | ||
| Q3 24 | $410.0K | $214.0K | ||
| Q2 24 | — | $1.1M | ||
| Q1 24 | — | $582.0K |
| Q4 25 | — | $-12.5M | ||
| Q3 25 | — | $-30.9M | ||
| Q2 25 | — | $-19.2M | ||
| Q1 25 | — | $-7.3M | ||
| Q4 24 | — | $-10.9M | ||
| Q3 24 | — | $-13.7M | ||
| Q2 24 | — | $-8.3M | ||
| Q1 24 | — | $-26.8M |
| Q4 25 | — | 87.5% | ||
| Q3 25 | — | 88.8% | ||
| Q2 25 | — | 10.8% | ||
| Q1 25 | — | 91.7% | ||
| Q4 24 | — | -127.0% | ||
| Q3 24 | — | -446.7% | ||
| Q2 24 | — | 94.4% | ||
| Q1 24 | — | 86.3% |
| Q4 25 | — | -4016.4% | ||
| Q3 25 | — | -14518.4% | ||
| Q2 25 | — | -13210.0% | ||
| Q1 25 | — | -6011.3% | ||
| Q4 24 | — | -2866.9% | ||
| Q3 24 | -34.1% | -7146.3% | ||
| Q2 24 | — | -1566.7% | ||
| Q1 24 | — | -4151.7% |
| Q4 25 | — | -4900.4% | ||
| Q3 25 | — | -31541.8% | ||
| Q2 25 | — | -15989.2% | ||
| Q1 25 | — | -4317.9% | ||
| Q4 24 | — | -2966.9% | ||
| Q3 24 | — | -6378.5% | ||
| Q2 24 | — | -751.7% | ||
| Q1 24 | — | -4603.3% |
| Q4 25 | — | $0.40 | ||
| Q3 25 | — | $-2.18 | ||
| Q2 25 | — | $-2.45 | ||
| Q1 25 | — | $-1.50 | ||
| Q4 24 | — | $-1.17 | ||
| Q3 24 | — | $-5.15 | ||
| Q2 24 | — | $-3.30 | ||
| Q1 24 | — | $-13.89 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $2.5M | $28.4M |
| Total DebtLower is stronger | — | $109.6M |
| Stockholders' EquityBook value | $6.0M | $-95.5M |
| Total Assets | $13.1M | $44.9M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $28.4M | ||
| Q3 25 | — | $36.2M | ||
| Q2 25 | — | $17.4M | ||
| Q1 25 | — | $31.0M | ||
| Q4 24 | — | $29.9M | ||
| Q3 24 | $2.5M | $40.4M | ||
| Q2 24 | — | $56.3M | ||
| Q1 24 | — | $74.1M |
| Q4 25 | — | $109.6M | ||
| Q3 25 | — | $109.1M | ||
| Q2 25 | — | $108.7M | ||
| Q1 25 | — | $105.5M | ||
| Q4 24 | — | $102.5M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | $-95.5M | ||
| Q3 25 | — | $-88.9M | ||
| Q2 25 | — | $-107.7M | ||
| Q1 25 | — | $-90.2M | ||
| Q4 24 | — | $-93.1M | ||
| Q3 24 | $6.0M | $-85.6M | ||
| Q2 24 | — | $-74.3M | ||
| Q1 24 | — | $-72.4M |
| Q4 25 | — | $44.9M | ||
| Q3 25 | — | $44.8M | ||
| Q2 25 | — | $25.8M | ||
| Q1 25 | — | $38.6M | ||
| Q4 24 | — | $38.3M | ||
| Q3 24 | $13.1M | $48.9M | ||
| Q2 24 | — | $65.4M | ||
| Q1 24 | — | $82.3M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-1.6M | $-14.2M |
| Free Cash FlowOCF − Capex | $-1.6M | — |
| FCF MarginFCF / Revenue | -392.9% | — |
| Capex IntensityCapex / Revenue | 4.4% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $-14.2M | ||
| Q3 25 | — | $-18.8M | ||
| Q2 25 | — | $-12.6M | ||
| Q1 25 | — | $-12.0M | ||
| Q4 24 | — | $-14.8M | ||
| Q3 24 | $-1.6M | $-16.3M | ||
| Q2 24 | — | $-23.2M | ||
| Q1 24 | — | $-17.7M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $-1.6M | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | -392.9% | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | — | 0.0% | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 4.4% | 0.0% | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
